{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:47:17Z","timestamp":1789127237590,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40123-022-00456-4","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T10:02:48Z","timestamp":1643450568000},"page":"479-487","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Use of Sustained Release Intravitreal Steroid Implants in Non-Infectious Uveitis Affecting the Posterior Segment of the Eye"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-0493","authenticated-orcid":false,"given":"Didar","family":"Abdulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Menezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-881X","authenticated-orcid":false,"given":"Simon R. J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"6","key":"456_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.preteyeres.2011.06.005","volume":"30","author":"MD de Smet","year":"2011","unstructured":"de Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452\u201370.","journal-title":"Prog Retin Eye Res"},{"key":"456_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/DDDT.S166092","volume":"13","author":"S Koronis","year":"2019","unstructured":"Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667\u201380.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"456_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5301\/ejo.5000278","volume":"23","author":"E Miserocchi","year":"2013","unstructured":"Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705\u201317.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"456_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2415-13-39","volume":"13","author":"S Tempest-Roe","year":"2013","unstructured":"Tempest-Roe S, Joshi L, Dick AD, Taylor SRJ. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol. 2013;13(1):39.","journal-title":"BMC Ophthalmol"},{"key":"456_CR5","first-page":"67","volume":"8","author":"S Pasadhika","year":"2014","unstructured":"Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biol Targets Ther. 2014;8:67\u201381.","journal-title":"Biol Targets Ther"},{"issue":"11","key":"456_CR6","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/imj.14215","volume":"49","author":"A Trivedi","year":"2019","unstructured":"Trivedi A, Katelaris C. The use of biologic agents in the management of uveitis. Intern Med J. 2019;49(11):1352\u201363.","journal-title":"Intern Med J"},{"issue":"6","key":"456_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/jamaophthalmol.2017.0603","volume":"135","author":"J Sheppard","year":"2017","unstructured":"Sheppard J, Joshi A, Betts KA, et al. Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials. JAMA Ophthalmol. 2017;135(6):511\u20138.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"456_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-200501000-00001","volume":"25","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Akpek EK. Immunosuppression for posterior uveitis. Retina Phila Pa. 2005;25(1):1\u201318.","journal-title":"Retina Phila Pa"},{"issue":"6","key":"456_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3109\/09273948.2014.902074","volume":"23","author":"PY Chang","year":"2015","unstructured":"Chang PY, Kresch Z, Samson CM, Gentile RC. Spontaneous dissociation of fluocinolone acetonide sustained release implant (Retisert) with dislocation into the anterior chamber. Ocul Immunol Inflamm. 2015;23(6):454\u20137.","journal-title":"Ocul Immunol Inflamm"},{"issue":"10","key":"456_CR10","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","volume":"122","author":"JH Kempen","year":"2015","unstructured":"Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, et al. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Ophthalmology. 2015;122(10):1967\u201375.","journal-title":"Ophthalmology"},{"issue":"6","key":"456_CR11","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","volume":"117","author":"JA Haller","year":"2010","unstructured":"Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.e3.","journal-title":"Ophthalmology"},{"issue":"5","key":"456_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","volume":"129","author":"C Lowder","year":"2011","unstructured":"Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545\u201353.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"456_CR13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ophtha.2017.12.038","volume":"125","author":"D Pohlmann","year":"2018","unstructured":"Pohlmann D, Vom Brocke GA, Winterhalter S, Steurer T, Thees S, Pleyer U. Dexamethasone inserts in noninfectious uveitis: a single-center experience. Ophthalmology. 2018;125(7):1088\u201399.","journal-title":"Ophthalmology"},{"issue":"12","key":"456_CR14","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","volume":"118","author":"JA Haller","year":"2011","unstructured":"Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453\u201360.","journal-title":"Ophthalmology"},{"issue":"4","key":"456_CR15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ajo.2009.11.019","volume":"149","author":"JH Kempen","year":"2010","unstructured":"Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. Rationale, design, and baseline characteristics. Am J Ophthalmol. 2010;149(4):550\u2013561.e10.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"456_CR16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","volume":"118","author":"PA Pearson","year":"2011","unstructured":"Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118(8):1580\u20137.","journal-title":"Ophthalmology"},{"issue":"9","key":"456_CR17","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.ophtha.2016.05.025","volume":"123","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Lin P, Keenan RT, Ashton P, Skalak C, Stinnett SS. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology. 2016;123(9):1940\u20138.","journal-title":"Ophthalmology"},{"issue":"9","key":"456_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","volume":"126","author":"DG Callanan","year":"2008","unstructured":"Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol. 2008;126(9):1191\u2013201.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"456_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12348-020-00225-z","volume":"10","author":"B Bodaghi","year":"2020","unstructured":"Bodaghi B, Nguyen QD, Jaffe G, Khoramnia R, Pavesio C. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye\u2014evaluating the 0.2 \u03bcg\/day fluocinolone acetonide intravitreal implant (ILUVIEN\u00ae). J Ophthalmic Inflamm Infect. 2020;10(1):32.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"456_CR20","doi-asserted-by":"publisher","unstructured":"Ajamil-Rodanes S, Testi I, Luis J, Robson AG, Westcott M, Pavesio C. Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis. Br J Ophthalmol. 2020. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317372.","DOI":"10.1136\/bjophthalmol-2020-317372"},{"issue":"17","key":"456_CR21","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.3390\/jcm10173966","volume":"10","author":"M Hikal","year":"2021","unstructured":"Hikal M, Celik N, Auffarth GU, Kessler LJ, Mayer CS, Khoramnia R. Intravitreal 0.19 mg fluocinolone acetonide implant in non-infectious uveitis. J Clin Med. 2021;10(17):3966.","journal-title":"J Clin Med"},{"issue":"1","key":"456_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12348-019-0168-9","volume":"9","author":"LF Weber","year":"2019","unstructured":"Weber LF, Marx S, Auffarth GU, et al. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J Ophthalmic Inflamm Infect. 2019;9(1):3.","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"6","key":"456_CR23","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0161-6420(03)00254-9","volume":"110","author":"MM Brown","year":"2003","unstructured":"Brown MM, Brown GC, Sharma S, Busbee B. Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology. 2003;110(6):1076\u201381.","journal-title":"Ophthalmology"},{"issue":"1","key":"456_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40123-020-00328-9","volume":"10","author":"AS Ansari","year":"2021","unstructured":"Ansari AS, Amir Z, Williams GS. Bilateral 0.19 mg fluocinolone acetonide intravitreal implant in the successful treatment of juvenile idiopathic arthritis-associated uveitis and secondary macular oedema: a case report and review of intravitreal therapies. Ophthalmol Ther. 2021;10(1):193\u2013200.","journal-title":"Ophthalmol Ther"},{"key":"456_CR25","unstructured":"ILUVIEN 190 micrograms intravitreal implant in applicator\u2014summary of product characteristics (SmPC). EMC. https:\/\/www.medicines.org.uk\/emc\/medicine\/27636. Accessed 3 Nov 2021."},{"key":"456_CR26","unstructured":"National Institute for Health and Care Excellence. Committee discussion: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis. NICE. https:\/\/www.nice.org.uk\/guidance\/ta590\/chapter\/3-Committee-discussion. Accessed 3 Nov 2021"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-022-00456-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-022-00456-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:43:09Z","timestamp":1647434589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-022-00456-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1007\/s40123-022-00456-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"18 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}